Quantitation of Selected PFAS in Human Whole-Blood Utilizing VAMS (Volumetric Absorptive Micro Sampling) and Latest-Generation Triple Quadrupole Instrumentation

Separation Science, in collaboration with SCIEX, offers an on-demand webinar that provides an effective approach for studying PFAS in human whole blood and also discusses the challenges of PFAS analysis in blood serum and how to overcome them.

Duration: 30 minutes

Andrew_PattersonAndrew Patterson
Technical Director, Eurofins Environment Testing America - Specialty Services Division
Andrew brings 20 years of experience in the environmental laboratory industry with a focus on HRGC/HRMS analyses and also LC-MS/MS analyses. These approaches have focused on PCBs, dioxins, brominated flame-retardants, PFAS and emerging contaminants. Prior to Eurofins, Andrew was the Technical Director for Vista Analytical Laboratory in Northern California where he developed all aspects of PFAS capability within the lab. Before his time at Vista, Andrew worked in both the HRMS and LCMS laboratories at Alta Analytical with a focus on implementing performance based EPA methods. Andrew holds a Bachelor’s of Science in Microbiology from Cal Poly San Luis Obispo, California, USA.





Presentation Overview

Historically, PFAS blood testing has been performed on the serum component of blood. Serum is a less complex matrix to work with compared to whole blood and many PFAS partition towards the serum. The downside is that a blood draw and processing is required, which adds cost and complexity to an already expensive test. Interested PFAS test candidates may be located in a remote area or unable to secure a mobile phlebotomist making the blood draw a deciding factor to get a test performed. Additionally, pediatric PFAS tests are not uncommon and a heel-prick or finger-prick is less stressful for all parties than a blood draw.
Eurofins has pioneered an approach that utilizes a field deployed, self-administered blood collection device paired with very sensitive instrumentation to achieve biologically relevant detection limits for PFAS. Analyte lists with both long and short-chained PFAS will allow researchers snapshots into PFAS with short half-lives while still supporting legacy PFAS on the CDC NHANES list. Hopefully, a better understanding of PFAS body burden will be realized with a whole blood approach as it is understood that some PFAS, like FOSA, partition towards whole blood rather serum.

By viewing this presentation you will learn...

  • how to accelerate your study on the exposure of PFAS by studying PFAS in human whole blood
  • about the challenges of PFAS analysis in blood serum and how to overcome them.

Who should view it?
The presentation is ideal for:

  • Exposomics laboratory scientists and QA/QC managers working in the environmental and clinical research areas
  • Those involved in method development, interested in implementing and optimizing PFAS or any other environmental contaminant applications
  • Those interested in learning about the findings surrounding PFAS.

To register for this on-demand webinar please complete the form on the right.

Registrants to this webinar are covered by the Eclipse Business Media Privacy Policy. Information you provide will be shared with the sponsors for this content. Eclipse Business Media Ltd may contact you to offer you content based on your specific interests. You may opt-out at any time.